The TVM Capital Life Science Venture Practice in Montréal reinforces its investment team with Dr. Marc Rivière, MD, who will start his tenure as a General Partner in August.
MONTREAL, July 8, 2013 /PRNewswire/ - Marc Rivière will join the Montréal-based Managing Partners, Dr. Hubert Birner and Dr. Luc Marengère as well as General Partner Dr. Cynthia Lavoie. Marc Rivière has been a Québec resident for close to 20 years. He brings a broad product development experience backed by many years in leadership roles with service providers and with entrepreneurially led companies such as Axcan Pharma. At TVM Life Science Management Inc., he will focus on evaluation of deal opportunities and investment management for therapeutics. He will also work closely with the firm's strategic partner Eli Lilly & Co. and its drug development division Chorus.
Dr. Luc Marengère, Managing Partner of TVM Life Science Management Inc. says: "Marc will be an outstanding addition to our investment team. His experience, network and understanding of how early stage life-science projects are to be managed, will be an invaluable addition to our practice. We all look forward to start working with Marc."
Montréal's TVM Life Science Management Inc., an advisor to TVM Life Science Ventures VII, follows a capital efficient investment approach to developing individual pharmaceutical assets to a human proof-of-concept stage.
About the Life Science Investment Group of TVM Capital
TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 25-years of transatlantic investment track record and in excess of US$1.1bn under management. The Life Science Investment Group's mission is to invest in the development of exciting early stage drug candidates and companies in the medical field that are or aspire to be innovative leaders in their market segment. Since 1984, TVM Capital Life Science made 117 investments in life science companies in Europe and the United States and exited from 87 companies, including 42 initial public offerings on the NASDAQ, and the London, Frankfurt, Zurich and Vienna Stock Exchanges and 25 trade sales and mergers. The Life Science team combines long-standing international investment and company building experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals based in in Montréal and Munich.
More information: www.tvm-lifescience.com or twitter: tvmcapital
SOURCE TVM Capital